Telomere replication: poised but puzzling

Shilpa Sampathi a, b, Weihang Chai a, b, *

a WWAMI Medical Education Program, Washington State University, Spokane, WA, USA
b School of Molecular Biosciences, Washington State University, Pullman, WA, USA

Received: October 15, 2010; Accepted: November 26, 2010

Abstract

Faithful replication of chromosomes is essential for maintaining genome stability. Telomeres, the chromosomal termini, pose quite a challenge to replication machinery due to the complexity in their structures and sequences. Efficient and complete replication of chromosomes is critical to prevent aberrant telomeres as well as to avoid unnecessary loss of telomere DNA. Compelling evidence supports the emerging picture of synergistic actions between DNA replication proteins and telomere protective components in telomere synthesis. This review discusses the actions of various replication and telomere-specific binding proteins that ensure accurate telomere replication and their roles in telomere maintenance and protection.

Keywords: telomere replication • telomerase • shelterin • C-strand fill-in • G-quadruplex • cancer

Introduction

Telomeres, telomerase and their roles in genome stability

Maintenance of stable chromosome ends, telomeres, is a key contributor of genome stability. Chromosomal abnormalities due to dysfunctional telomeres have been implicated in cancer and premature aging disorders. Telomeres are special nucleoprotein structures composed of double-stranded (TTAGGG)n DNA repetitive sequence ranging from ~3 to 15 kb and a number of telomere associated proteins. The ds telomeric DNA terminates at a 3’ single-stranded G-rich overhang of about 12–500 bases [1–3]. This protruding 3’ end can invade the duplex DNA and form a lariat-like structure called ‘t-loop’, establishing a protective cap that shields chromosome ends from being recognized as damaged DNA and prevents nucleolytic degradation and inappropriate fusions of telomeres. The t-loop is stabilized by a complex of ds and ss stranded telomere binding proteins known as the ‘shelterin’ proteins (telomere repeat binding factor 1 and 2 [TRF1, TRF2], protection of telomeres 1 [POT1], TRF1 and TRF2 interacting nuclear protein 2 [TIN2], TINT1-TIN2 interacting protein, PIP1-POT1 interacting protein, PTOP-POT1 and TIN2 interacting protein [TPP1] and repressor activator protein 1 [Rap1]) [4]. The primary role of shelterin is to mark telomeres as the natural chromosome ends and suppress the DNA damage response pathways at telomeres [5]. Readers are referred to the excellent comprehensive reviews about the end-protection mechanisms conferred by the shelterin complex [5–6].

Due to the inability of the conventional DNA polymerases to completely duplicate linear chromosomal DNA and additional nucleolytic degradation of telomeric DNA, telomeres in human...
somatic cells progressively shorten as cells divide [7]. Critically short telomeres result in telomere deprotection and activate DNA damage response pathways, leading to cellular senescence or apoptosis. Such progressive loss of telomere DNA is visualized as a mechanism to limit the proliferative ability of the dividing cells [7]. Telomere damage response can also be triggered by disrupting the functions of shelterin proteins.

The majority of tumour cells acquire cellular immortality and stabilization of telomere length by activating a normally dormant enzyme, telomerase, which extends the 3’ end of the chromosomes to replenish the telomeric repeats in a sequence-specific manner. Telomerase is a special reverse transcriptase consisting of an RNA subunit hTR that serves as the template and a catalytic protein subunit telomerase reverse transcriptase (hTERT). It is expressed during early embryogenesis and subsequently down-regulated in most somatic cells [8]. The activity of telomerase is tightly regulated in vivo at the level of its expression as well as its biogenesis [9–13].

The fact that the majority of cancer cells require telomerase activity to maintain telomeres makes telomerase an attractive target in clinical medicine. Telomerase inhibition therapies targeting hTERT, hTR or its associated proteins are picking up pace. Inhibition can be carried out by using telomerase inhibitor ligands such as Imetelstat (lipid modified 13 mer oligonucleotide N3→P5’ thiophosphoramidate [GRN163L]) [14–18] and anti-sense oligonucleotides [19–21]. Applying more than one strategy is also in place to enhance the anti-cancer effect. Strategies such as combining RNAi with hammerhead ribozymes [22] or using natural telomerase inhibitor with chemotherapeutic agents have been reported [23]. Telomerase immunotherapy has also been shown to have promising developments [24].

Apart from cancers, dysfunctional telomerases are associated with a number of disorders such as dyskeratosis congenita (DC). Mutations seen in DC patients involve genes such as hTR [25–26], hTERT [27], dyskeratosis congenita 1 (DKC1) (encoding dyskerin), components of HACA small nucleolar ribonucleoprotein complex (NOP10 and NHP2) [28–30]. The latter three genes are key components of telomerase ribonucleoprotein complex [31]. Defective dyskerin, NOP10, NHP2 impair the assembly of telomerase complex. Mutations in hTR impair the level and accumulation of telomerase RNA and mutations in hTERT leads to haploinsufficiency in telomerase activity [32–33]. In a recent report, mutations in a shelterin component TIN2 also lead to DC [34]. Taken together, it is suggested that DC is a telomere maintenance disorder. Patients with DC display bone marrow failure, pulmonary fibrosis, mucocutaneous abnormalities and defects in the highly replicating tissues such as the hematopoietic cells. Extensive chromosomal recombinations and greater susceptibility to acute myeloid leukemia and other cancers are associated with DC patients as well [35–36]. Other dysfunctional telomeric disorders that are associated with inherited mutations in genes responsible for telomere maintenance include aplastic anaemia, acute myeloid leukemia and idiopathic pulmonary fibrosis [35–36]. Therefore, telomere maintenance and telomerase are currently the promising targets in cancer and aging related therapeutics.

**Telomere DNA replication: not a cake walk for the replication fork**

Faithful replication of chromosomal DNA is critical for genome stability. Replication of telomeric DNA is thought to be initiated from origins located in the sub-telomeric region [37]. The TTAGGG (G-rich) strand is replicated by discontinuous lagging strand synthesis initiated by small RNA primers. After the last RNA primer is removed, there is no mechanism to fill in the gap, leaving the daughter telomeres shorter than the parental ones. Meanwhile, the CCCTAA (C-rich) strand is replicated by continuous leading strand synthesis, making them blunt-ended. The C-rich strand is further processed/resected by nucleases and helicases including mammalian Apollo to generate longer G-overhangs [38]. These ss G-overhangs are finally converted into the protective t-loops to stabilize telomeress.

Due to the unusually long G-rich repetitive tracts and the unique telomere chromatin structures at chromosome ends, replication fork faces a number of potential challenges while passing through the telomere region. Examples of these challenges that are very stable in vivo and difficult to resolve include G-quadruplexes, heterochromatinized DNA and the special t-loop structure.

G-quadruplexes, also referred to as G-quartets or G4, are stable inter- or intra-molecular structures held intact by four guanine residues through Hoogsteen base-pairing [39]. During replication, separation of ds telomeric DNA exposes the ss G-rich strand, triggering the formation of G-quadruplexes. Their resolution requires the actions of helicases such as Bloom syndrome protein (BLM) and Werner syndrome protein (WRN) to further the movement of replication fork. The activities of ss DNA binding protein replication protein A (RPA) and the shelterin component POT1 are also necessary towards this end [40–41]. Thus, various players contribute towards the reduction of this structural difficulty for the passage of the replication fork through the telomere region to ensure a faithful replication. On the other hand, strategies to promote and stabilize the G4 structure with small molecules such as telomestatin and G4 ligand 3,11-difluoro-6,8,13-trimethyl-8H-quinol[4,3,2-kl]acridinium methosulfate (RHS54) induce defective telomere replication, and are effective cancer therapeutic approaches [23, 42–43].

Chromatin in the telomeric and sub-telomeric regions is highly repressed and termed as heterochromatin. Heterochromatinized environment is proposed to be a mechanism that negatively regulates telomere elongation, as the loss of chromatin modifiers leads to a substantial elongation of telomeress [44]. Furthermore, lack of DNA methylation deregulates telomere length homeostasis and leads to accelerated telomere recombination events [45]. It appears that a higher-order epigenetic regulation may control both telomere length homeostasis and telomeric protective function. Although this regulatory mechanism is poorly understood, a formal possibility is that the heterochromatinized environment poses a challenge for the replication fork to pass through the telomeric repeats. Efficient and accurate resolution of heterochromatin structure is necessary for the faithful replication of telomeric DNA and proper maintenance of chromosome ends.
In addition, t-loop itself poses a challenge to DNA replication. This special chromatin structure bound by various proteins is unlikely to rotate freely and is considered as a topological barrier. As the replication fork approaches telomere end, superhelical stress in the unreplicated DNA accumulates. Unwinding of t-loop is essential for resolving such topological stress and allowing efficient and complete replication of telomeric DNA.

The above events may result in replication fork stalling which then activates ataxia telangiectasia mutated/ataxia telangiectasia and Rad3 related (ATM-/ATR)-mediated DNA damage response, leading to cell growth arrest or creating a situation that may lead to accelerated telomere attrition. In fact, telomeres resemble fragile sites resulting from defects in replication and are prone to deletions and chromosome rearrangements [46]. In higher eukaryotes these issues seem to be tackled by mainly two protein consortiums:

(1) Actions of replication proteins at telomeres: To deal with the difficulties in telomere replication, replication proteins ought to have robust activities. In addition, they perform multiple functions and participate in multiple pathways including DNA repair to ensure genome stability. The mechanism of the actions of replication proteins at telomeres is still poorly understood, and whether it is the same as general replication or enhanced at telomeres is yet to be explored.

(2) Actions of telomeric proteins in resolving the challenges faced by the replication fork: Passage of replication fork through telomeric tracts requires coordinated actions of telomeric proteins with replication factors. This may involve either the resolution of structural difficulties or just aiding in the assembly of the higher-order replication complex (RC).

### Functions of replication proteins in telomere maintenance

Studies of the activities of replication proteins from lower eukaryotes such as yeast and ciliates indicate that telomerase extension of telomeres is in close collaboration with replication machinery. However, the complexity of telomere structure in higher eukaryotes requires more enhanced mechanisms to be functional. Here, we review a number of proteins playing multiple roles in replication, repair and other processes, and discuss their roles specific to telomere DNA replication.

**DNA polymerase α-primase (polα/primase)**

The polα/primase complex consists of four subunits responsible for initiating the lagging strand DNA synthesis de novo [47]. The p48 and p58 subunits form the catalytic primase that synthesizes a short RNA primer. The 180Kd subunit of the complex, p180 or polα, synthesizes short stretches of DNA following the RNA primer, while another subunit, p70 or the B subunit or PolI2, is thought to regulate the p180 activity [47]. The pivotal role of polα in telomere maintenance was initially reported in lower eukaryotes. In budding yeast polα is essential for telomerase extension of telomere ends [48]. Mutations in polα lead to a telomerase-independent increase in the amount of G-overhangs specifically in S phase [49–50], and show telomerase-dependent telomere elongation [51]. Furthermore, polα interacts with Cdc13p, a telomere binding protein that regulates telomerase-mediated telomere extension [52]. Analogous physical interaction between lagging strand replication machinery and telomerase has also been detected in the ciliate *Euplotes crassus* [53] and fission yeast [54]. In fission yeast, mutation in polα leads to telomere length abnormalities and decrease in telomerase protein stability [54]. Taken together, it is likely that in lower eukaryotes, replication apparatus and telomeric complexes aid in the fine tuning of telomerase action to generate the homeostatic telomere length.

Polα has been implicated in telomere maintenance in higher eukaryotes as well. In a mouse mutant cell line harbouring a temperature sensitive allele of polα, inhibition of polα induces an increase in the amount of G-overhangs and increases POT1 and TRF1 bound to telomeres [55]. Such alteration in telomere structure contributes to genome instability as revealed by an increase in Robertsonian chromosome fusions. In human cells, polα localizes to telomeres in both S phase and G2 phase [56], presumably for DNA synthesis and the delayed C-strand synthesis (see below) [57]. Due to the complexity of the genome in higher eukaryotes, homeostatic telomere length may be achieved by unique mechanisms. This may involve additional roles of replication proteins in close collaboration with telomeric factors. At present, the function of polα in telomere maintenance in higher eukaryotes remains poorly understood.

**Replication protein A**

RPA binds to and stabilizes the ssDNA intermediates encountered during various DNA metabolic processes by using the evolutionarily conserved oligonucleotide/oligosaccharide (OB)-fold domains [58–59]. Initially thought as a DNA replication component, RPA has emerged as an important player in DNA repair, checkpoint activation, and cell cycle regulation. It is now known to be important for telomere maintenance and participates in multiple activities at telomeres, thus validating its role as a genome guardian [60].

RPA is a heterotrimeric complex consisting of three subunits – RPA70, RPA32 and RPA14 [61]. During DNA replication, RPA coats ssDNA and acts as a molecular platform for the assembly and activation of the pre-RC, thus recruiting the polα/primase complex to the origin of replication [62]. During DNA repair, RPA interacts and activates components like PCNA, RFC and polε, perhaps to stabilize the ssDNA structures arising during repair [59]. RPA also has a role in checkpoint activation by mediating an ATR-mediated DNA damage response [63].

In budding yeast, a double mutant for RFA1 (hRPA70 homologue) and yKu70 showed a synergistic shortening in telomere length, indicating a role of RPA in telomere length regulation [64]. In fission yeast, a mutant similar to the above double mutant displays both DNA damage sensitivity and shortened telomeres [65]. Both Rfa1 and Rfa2 (hRPA34 homologue) localize to telomeres.
during the S phase, and a mutant Rfa2 lacking the N-terminus showed impaired binding by Est1p, suggesting a role of RPA in telomerase action [66].

Our understanding on human RPA primarily comes from biochemical assays with purified proteins. In vitro, human RPA modulates telomerase activity, stimulates WRN's activity in disrupting D-loops, and is able to unfold telomeric G-quadruplexes [40, 67–69]. During replication of genomic DNA, RPA is thought to coat ss DNA as replication fork passes. However, biochemical analysis shows that its affinity to ss G-rich DNA is about two times weaker compared to the shelterin protein POT1 [70], raising the question of how the ss telomeric DNA is protected during replication at the telomeric region. It will be interesting to know how RPA interplays with shelterin components such as POT1 and other ss DNA binding proteins (e.g. Cdc13-Stn1-Ten1 [CST]) during the replication of telomeres.

RecQ helicases

RecQ is a conserved family of helicases including RecQ1, RecQ4, RecQ5, BLM and WRN. These enzymes are essential for maintaining genomic integrity, as mutations in these proteins are associated with hereditary cancer predisposition syndromes [71–73].

Cumulative evidence suggests the importance of RecQ helicases in telomere replication. In budding yeast, RecQ helicase Sgs1 helps in efficient resolution of telomeric recombination. Failure to do so leads to premature aging in yeast mother cells [74–76]. Studies on cells derived from Werner syndrome patients show that WRN-deficient cells specifically lose telomeres replicated by lagging strand synthesis, and a dominant-negative mutation in WRN leads to increased telomere loss and aberrant chromosomal recombination [70, 77–78]. Comparable telomere-associated phenotype has been observed in mice null for both WRN and mTerc [79–80]. Given that WRN localizes to telomeres during the S phase [78], and the helicase activity of WRN unwinds G-quadruplexes [81–82], it is highly possible that WRN is an important player in resolving structural barriers generated during replication. In agreement with this view, the amount of ss G-rich DNA significantly increases during S phase upon the removal of WRN, suggesting replication fork stalling at lagging telomeres [70]. Notably, both TRF2 and POT1 are able to stimulate WRN's helicase activity in vitro [81, 83–84]. Taken together, it appears that the WRN helicase activity is enhanced by telomere specific proteins for efficient telomere replication.

Another mammalian RecQ helicase, BLM, may play an overlapping function alongside WRN. BLM gene is mutated in Bloom's syndrome, an autosomal recessive disorder associated with cancer predisposition and premature aging [73]. Bloom's syndrome cells show increased genomic instability, sister chromatid exchanges and elevated levels of chromosomal aberrations including translocations [85–87]. Like WRN, BLM is able to unwind G-quadruplexes [88–89]. It binds to TRF1 and its helicase activity can be stimulated by certain shelterin proteins on a variety of DNA structures in vitro [81, 83, 90]. Thus, its helicase activity is likely to be needed for efficient replication of telomeric DNA as well. Indeed, BLM-deficient cells show a high frequency of fragile telomeres [46].

Flap endonuclease 1 (FEN1)

FEN1 is a conserved, structure-specific endonuclease involved in various DNA metabolic pathways [91–92]. It recognizes a dsDNA with a 5’ displaced flap structure, a common intermediate arising during lagging strand replication and long patch base excision repair [92]. FEN1 possesses three distinct nuclease activities: 5’→3’ FEN, 5’→3’ exonuclease and gap-dependent endonuclease (GEN) [93]. The FEN activity is used in the removal of RNA primers during Okazaki fragment processing either alone on short flaps, or with Dna2 on longer flaps [94–96]. FEN1 is also needed in DNA repair, particularly in the removal of damaged base [93].

Studies from budding yeast suggest that the FEN1 homologue Rad27 is likely to be responsible for the generation of G-overhangs at the lagging telomere ends [97–98]. Possibly due to the role of Rad27 in G-overhang generation, deletion of rad27 causes an accelerated senescence phenotype in strains also lacking components required for telomerase activity [98].

In human cells, FEN1 localizes at telomeres during the S and G2 phases of cell cycle and associates with at least one shelterin protein, TRF2 [56, 99]. In telomerase-expressing cells, FEN1 forms a complex with the catalytic component of telomerase, hTERT [100]. Although the functional importance of this association is yet to be explored, it has been shown that FEN1 depletion leads to progressive telomere shortening in cancer cells [100], suggesting that FEN1 may assist telomerase in elongating telomeres. In addition, FEN1-deficient mouse embryonic fibroblasts showed increased telomere end-to-end fusions [100].

In telomerase negative human fibroblasts, depletion of FEN1 leads to the loss of sister telomeres replicated by lagging strand synthesis, and as a consequence, resulting in an increase of dysfunctional telomeres as revealed by γ-H2AX precipitated telomere DNA [101]. This is attributed to FEN1’s GEN activity, which has been implicated in replication fork re-initiation [102–103]. Mutational analyses indicate that both FEN1’s GEN activity and its ability to interact with WRN helicase are required for its role at telomeres, suggesting that stimulation of FEN1 activity by WRN is essential for replication fork re-initiation. This is reminiscent of the observation that WRN stimulates FEN1 through direct interaction [104], and that FEN1’s GEN activity is shown to be required for resolving stalled replication forks [102]. Consistent with its role in lagging strand replication of telomeres, FEN1 appears to be able to efficiently process 5’ DNA flap substrates bearing G4 quartets [105]. Taken together, FEN1’s collaborative role with other factors to re-initiate stalled replication forks may be one of its functions, yet the functional significance of its interactions with telomerase and TRF2 remain to be determined.

Dna2

Dna2 is a helicase and nuclease whose function is implicated in the maturation of Okazaki fragments alongside FEN1 on longer flap intermediates [96]. In Saccharomyces cerevisiae, Dna2 localizes at telomeres in a cell cycle regulated manner and has a role in both telomere replication and perhaps capping as well [106]. In S. pombe Dna2 is also involved in the generation of
Functions of telomere binding proteins in telomere replication

Shelterin proteins that tightly bind to telomeric DNA were once considered as blockades for telomere replication. It was thought that they might be displaced from telomeres as replication fork moves along the telomere region until recent studies suggest that efficient and faithful replication of the repetitive telomeric DNA requires the participation of these telomere protective proteins.

TRF1
TRF1 is an abundant shelterin protein that binds to the duplex telomeric repeats with a role in telomere length regulation. Recently, its role has emerged to be predominant in efficient telomere replication. Loss of TRF1 leads to aberrant telomere structural changes resembling common fragile sites, which activate the ATR kinase in S phase [46]. Single-molecule analysis of replicated DNA reveals that the absence of TRF1 greatly weakens replication efficiency, suggesting that TRF1 promotes efficient replication of telomeric DNA by preventing fork stalling [46]. This study further stresses the notion that the telomeric region poses a great challenge to replication machinery.

Consistently, deletion of Taz1 (TRF1 homologue) in fission yeast causes a block in telomere replication, resulting in aberrant telomeric fragments [108]. As a consequence, Taz1 depleted cells show rapid telomere loss in the absence of telomerase [108]. Collectively, it is obvious that TRF1 not only helps in telomere capping and telomere length control, but also promotes efficient telomere replication, perhaps by recruiting helicases such as BLM and RTEL1 and other factors to the stalled replication forks [46].

TRF2
Like TRF1, TRF2 is also a duplex DNA binding shelterin protein essential for telomere end protection and length regulation. It plays a monumental role in the formation of the protective t-loop structure. Recent studies have discovered TRF2 as an essential player in assisting efficient replication of telomere DNA, but likely with a mechanism different from TRF1. First, TRF2 preferentially binds to positively supercoiled DNA in vitro and is enriched at telomeres upon the loss of topoisomerase 2 (Top2α) activity [109]. TRF2 also induces positive supercoiling of DNA, suggesting that its binding to positive supercoils may be energetically favoured [110]. Such activities are proposed to be used for sensing the topological stress created by fork progression and then recruit proteins such as Apollo and Top2α to release the topological strain [109]. Second, TRF2 is potentially involved in the dissolution of t-loops and Holliday junctions [110]. This event is speculated to be aided by local telomere unwinding factors such as BLM and WRN. Furthermore, TRF2 is likely to be involved in the formation of pre-RC in order to initiate replication at telomeres, as TRF2 interacts with the origin recognition complex (ORC) and reduction of TRF2 leads to reduced ORC binding and pre-RC assembly at telomeres [111–112]. In agreement with this view, a recent in vitro study using Xenopus cell-free extract shows that TRF2 binds to the telomeric DNA substrates to initiate replication in an origin-dependent manner [113]. Notably, pre-RC proteins such as ORC2, minichromosome maintenance (MCM)6, Cdc6 also assembled following the binding of TRF2 [113]. How TRF2 could promote all these activities probably relies on the formation of different protein complexes through its wide array of protein–protein associations [114]. Some of these associations in the context of replication are Apollo, WRN, BLM and FEN1 [84, 90, 99, 109]. It has been proposed that TRF2 essentially acts as a protein hub and coordinates the associations with various proteins by recruiting them to telomeres at different stages during the cell cycle for efficient telomere maintenance [115].

Apollo
Apollo is a 5′→3′ exonuclease acting in a TRF2-dependent manner in protecting telomere ends from DNA damage response during the S phase [116–117]. Its nucleolytic activity is implicated in the protection of leading strand telomeres and efficient G-overhang maintenance in mammalian cells [38], but appears to be dispensable for G-overhang generation in human cells [109]. Expression of the nuclease-inactive Apollo results in S-phase specific defective telomeres, leading to increased telomeric fusions and accelerated onset of senescence [109, 117]. Apollo’s nuclease activity is also crucial for protecting interstitial telomere repeats [109], strongly suggesting that Apollo could be involved in the progression of replication fork through telomeric chromatin. Such protection is achieved by the cooperation between TRF2, the nuclease activity of Apollo, together with Top2α to effectively resolve the positive superhelical stress generated during the replication of telomeric DNA [109]. However, the molecular mechanism of this coordination remains to be elucidated.

POT1
POT1 binds to ss G-overhang and plays an essential role in telomere capping and chromosome end-protection [12, 118–123]. It represses the activation of ATR-mediated DNA damage response induced by dysfunctional telomeres [123–124]. Moreover, biomedical analysis shows that human POT1 protein stimulates the activities of the helicases WRN and BLM in unwinding G-quadruplexes in vitro [81]. In the absence of WRN, POT1 is required for normal replication of leading daughter telomeres [70]. It is further demonstrated that purified POT1 possesses a higher affinity to ss G-rich DNA than RPA, which accumulates at telomeres when WRN is deficient [70]. It is possible that POT1, together or in competition with RPA, binds to ss G-strand during replication and prevents a full replication fork stalling and activating the ATR kinase. Alternatively, POT1 may have additional functions in compensating...
for the absence of necessary factors like WRN to carry out telomere replication, such as preventing the formation of G-quadruplex structures in telomeric DNA [41].

The above findings have revealed that shelterin proteins are required for solving telomere replication problems in addition to their protective functions in telomere capping, telomere length regulation and repressing DNA damage response. It will be interesting to know the roles of other shelterin components such as TPP1, TIN2 and Rap1 in telomere replication. A model summarizing the roles of various proteins in telomere DNA replication is provided in Fig. 1A.

The delayed telomeric C-strand synthesis at late S/G2 phase – an additional regulatory step of telomere maintenance

Elongation of telomeres requires extension of both strands of telomeric DNA. While telomerase elongates the G-strand, extension of C-strand is thought to be accomplished by a DNA polymerization step similar to lagging strand synthesis. Lack of this synthesis
would give rise to excessive long ss G-rich DNA, which could harm telomere protection. Indeed, this additional DNA synthesis process termed C-strand fill-in or C-strand synthesis has been observed in *S. cerevisiae*. Remarkably, C-strand synthesis occurs at the same time as telomerase extension of telomeres and appears to regulate telomerase activity in yeast [48, 125–126]. Recently, two independent studies have revealed that human telomeres undergo C-strand synthesis as well [57, 127]. However, in human cells, this synthesis step is delayed until the late S/G2 phase, following global DNA replication and telomerase extension of telomeres [127], suggesting that it is independent of telomerase action (Fig. 1B). Therefore, the delayed C-strand synthesis could be more divergent in evolution. The current prevailing model of telomerase extension following telomere replication and being separate from C-strand synthesis may be an enhanced mechanism to avoid the persistence of excessive ss G-rich DNA generated during replication and further counteract accelerated telomere shortening in mammals. Regardless of the purpose of C-strand fill-in, this delayed synthesis may be unique to telomeres and mechanistically different from general lagging strand replication, thus providing a new strategy for cancer therapeutics. Inhibition of C-strand synthesis in tumour cells is expected to disrupt telomere maintenance without actually affecting the overall telomere replication. This opens up a new area of research toward understanding the precise mechanistic details of C-strand synthesis and determining the factors responsible for regulating this event.

Our lab has recently shown that inhibition of polα activity during the late S/G2 phase completely blocks C-strand synthesis, suggesting that C-strand synthesis requires the activity of polα [57]. Furthermore, inhibition of the activity of one of the major kinases regulating the cell cycle progression, cyclin-dependent kinase 1 (CDK1), accumulates ss G-overhangs at late S/G2 phase, indicating that C-strand synthesis may be under the control of CDK1 [57]. These observations provide molecular insight into the mechanism regulating C-strand synthesis in human cells.

The CST complex

While the molecular targets of CDK1 at telomeres and how it controls polα-mediated C-strand synthesis still remain to be determined, an evolutionarily conserved RPA-like heterotrimeric complex, the CST complex, has emerged as a key player in regulating C-strand synthesis [57, 128–129]. In budding yeast, telomerase action and C-strand fill-in is excellently coordinated by the CST complex. CST specifically binds to telomeric ssDNA via the putative OB-fold domains and protects telomere ends in multiple ways by repressing telomerase activity, restricting extensive nuclelease degradation of C-strand and mediating C-strand fill-in [52, 126, 130–136]. Cdc13 has a dual role in both positively and negatively regulating telomerase. It binds to G-rich strand DNA and recruits telomerase (Est2 and Est1) to telomeres [130]. Dysfunction of Cdc13 leads to extensive C-strand degradation and G-overhang elongation [126, 137]. Yeast Stn1 negatively regulates telomerase action and coordinates DNA replication of the opposing telomeric C strand [133–134, 136–137]. Based on the associations of both Cdc13 and Stn1 with polα, it is proposed that this complex could mediate the C-strand fill-in [52, 138].

The presence of the CST homologues in higher eukaryotes has recently been validated [128–129, 139–140]. The mammalian CST is formed by Ctc1-Stn1-Ten1 [129]. This complex binds to ssDNA in a sequence-independent manner and localizes at telomeres [129]. Depletion of components of CST leads to a significant increase of G-overhangs in human telomeres and induces telomere dysfunction [57, 128–129]. Interestingly, hCtc1 and hStn1 is also known as α accessory factors AAF132 and AAF44 due to their ability to stimulate polα activity in vitro [141]. Thus, it is highly likely that mammalian CST may promote the recruitment of polα/primase complex to the telomere DNA to carry out C-strand synthesis (Fig. 1B).

Given the multifunctional roles of yeast CST at telomeres, it is likely that mammalian CST may play additional roles such as telomerase regulation, telomere capping and perhaps restricting C-strand resection. Consistent with this notion, hStn1 associates with one telomere capping protein TPP1 and C-terminal deletion of hStn1 results in telomere elongation [142]. Furthermore, recent genome-wide association analysis has linked the genetic variation of hStn1 with alteration in telomere length [143]. These observations underscore the necessity to further our understanding of the telomeric function of mammalian CST.

Conclusions and perspectives

The last couple of decades have seen a surge of complex and dynamics world at telomeres. With the discovery of the growing number of proteins involved in telomere maintenance, it becomes evident that coordination between their actions is necessary for fulfilling the protective function of telomeres. Efficient strategies for cancer therapeutics can be developed only when a detailed mechanistic knowledge prevails on all the events taking place at telomeres. Examples of important areas that remain to be investigated are: t-loop structure formation and resolution before and after replication, the effects of telomeric heterochromatin on telomere maintenance, the concerted action of replication proteins and telomeric factors in safeguarding telomere integrity, the interplay between CST and shelterin components for regulating telomerase activity and telomere stability and regulation of C-strand synthesis. With the increasing wealth of knowledge and the advancement of technology, we expect rapid progress in unravelling the enigmatic events of telomere maintenance in the years to come.

Acknowledgements

We apologize for not including all of the important papers in this manuscript due to space constraints. Work at Chai laboratory was supported by NIH grant R15CA132090 and American Cancer Society grant IRG-77-003-32.

Conflict of interest

We declare no conflict of interest.
References

1. Makarov VL, Hirose Y, Langmore JP. Long G tails at both ends of human chromosomes suggest a G strand degradation mechanism for telomere shortening. Cell. 1997; 88: 657–66.

2. Wright WE, Tesmer VM, Huffman KE, et al. Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes Dev. 1997; 11: 2801–9.

3. Chai W, Du Q, Shay JW, et al. Human telomeres have different overhang sizes at leading versus lagging strands. Mol Cell. 2006; 21: 427–35.

4. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005; 19: 2100–10.

5. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet. 2008; 42: 301–34.

6. de Lange T. How telomeres solve the end-protection problem. Science. 2009; 326: 948–52.

7. Bianchi A, Shore D. How telomerase reaches its end: mechanism of telomerase regulation by the telomeric complex. Mol Cell. 2008; 31: 153–65.

8. Wright WE, Piatyszek MA, Rainey WE, et al. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996; 18: 173–9.

9. Smogorzewska A, van Steensel B, Bianchi A, et al. Control of human telomere length by TRF1 and TRF2. Mol Cell Biol. 2000; 20: 1659–68.

10. Houghtaling BR, Cuttnero L, Chang W, et al. A dynamic molecular link between the telomere length regulator TRF1 and the chromosome end protector TRF2. Curr Biol. 2004; 14: 1621–31.

11. Li B, de Lange T. Rap1 affects the length and heterogeneity of human telomeres. Mol Biol Cell. 2003; 14: 5060–8.

12. Leayza D, De Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature. 2003; 424: 1013–8.

13. Collins K. The biogenesis and regulation of telomerase holoenzymes. Nat Rev Mol Cell Biol. 2006; 7: 484–94.

14. Goldblatt EM, Gentry ER, Fox MJ, et al. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther. 2009; 8: 2027–35.

15. Goldblatt EM, Erickson PA, Gentry ER, et al. Lipid-conjugated telomerase template antagonists sensitize resistant HER2-positive breast cancer cells to trastuzumab. Breast Cancer Res Treat. 2009; 118: 21–32.

16. Gryaznov SM, Jackson S, Dikmen G, et al. Oligonucleotide conjugate GRN163L targeting human telomerase as a potential anticancer and antimetastatic agent. Nucleosides Nucleotides Nucleic Acids. 2007; 26: 1577–9.

17. Hochreiter AE, Xiao H, Goldblatt EM, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res. 2006; 12: 3184–92.

18. Herbert BS, Gellert GC, Hochreiter A, et al. Lipid modification of GRN163, an N3′→P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005; 24: 5262–8.

19. Kraemer K, Fuessel S, Schmidt U, et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res. 2003; 9: 3794–809.

20. Kondo Y, Kondo S. Telomerase RNA inhibition using antisense oligonucleotide against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo. Int J Oncol. 2007; 31: 107–112.

21. Iwado H, Daido S, Kondo Y, et al. Combined effect of 2′-5′-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells. Methods Mol Biol. 2007; 405: 95–112.

22. Li S, Nosrati M, Kashani-Sabet M. Knockdown of telomerase RNA using hammerhead ribozymes and RNA interference. Methods Mol Biol. 2007; 405: 113–31.

23. Tauchi T, Shin-ya K, Sashida G, et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute lymphoblastic leukemia. Oncogene. 2006; 25: 5719–25.

24. Liu JP, Chen W, Schwarz AP, et al. Telomerase in cancer immunotherapy. Biochim Biophys Acta. 2010; 1805: 35–42.

25. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2004; 427: 432–5.

26. Wong JM, Kyasa MJ, Hutchins L, et al. Telomerase RNA deficiency in peripheral blood mononuclear cells in X-linked dyskeratosis congenita. Hum Genet. 2004; 115: 448–55.

27. Vulliamy TJ, Walne A, Baskaradas A, et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis. 2005; 34: 257–63.

28. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999; 402: 551–5.

29. Walne AJ, Vulliamy T, Marrone A, et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Genet. 2007; 16: 1619–29.

30. Balci S, Engiz O, Erekul A, et al. An atypical form of dyskeratosis congenita with renal agenesis and no mutation in DKC1, TERC and TERT genes. J Eur Acad Dermatol Venereol. 2008; 23: 607–8.

31. Wang C, Meier UT. Architecture and assembly of mammalian H/ACA small nucleolar and telomerase ribonucleoproteins. EMBO J. 2004; 23: 1857–67.

32. Wong JM, Collins K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev. 2006; 20: 2348–58.

33. Armanios M, Chen JL, Chang YP, et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci USA. 2005; 102: 15960–4.

34. Savage SA, Giri N, Baerlocher GM, et al. TIN2F, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet. 2008; 82: 501–9.

35. Calado RT. Telomeres and marrow failure. Hematology Am Soc Hematol Educ Program. 2009; 338–43.

36. Mason PJ, Wilson DB, Bessler M. Dyskeratosis congenita – a disease of dysfunctional telomere maintenance. Curr Mol Med. 2005; 5: 159–70.

37. Wellingter RJ, Wolf AJ, Zakian VA. Origin activation and formation of single-strand TG1–3 tails occur sequentially in late S phase on a yeast linear plasmid. Mol Cell Biol. 1993; 13: 4057–65.

38. Wu P, van Overbeek M, Rooney S, et al. Apollo contributes to G overhang maintenance and protects leading-end telomeres. Mol Cell. 2010; 39: 606–17.
39. Henderson E, Hardin CC, Walk SK, et al. Telomeric DNA oligonucleotides form novel intramolecular structures containing guanine-guanine base pairs. Cell. 1987; 51: 899–908.

40. Salas TR, Petrusseva I, Lavrik O, et al. Human replication protein A unfolds telomeric G-quadruplexes. Nucleic Acids Res. 2006; 34: 4857–65.

41. Zaug AJ, Podell ER, Cech TR. Human POT1 disrupts telomeric G-quadruplexes allowing telomerase extension in vitro. Proc Natl Acad Sci USA. 2005; 102: 10864–9.

42. Salvati E, Leonetti C, Rizzo A, et al. Telomere damage induced by the G-quadruplex ligand RHP54 has an antitumor effect. J Clin Invest. 2007; 117: 3236–47.

43. Gomez D, Lemarteau T, Lacroix L, et al. Telomerase downregulation induced by the G-quadruplex ligand 12459 in A549 cells is mediated by hTERT RNA alternative splicing. Nucleic Acids Res. 2004; 32: 371–9.

44. Benetti R, Garcia-Cao M, Blasco MA. Telomere length regulates the epigenetic status of mammalian telomeres and sub-telomeres. Nat Genet. 2007; 39: 243–50.

45. Gonzalo S, Jiao I, Fraga MF, et al. DNA methyltransferases control telomere length and telomere recombination in mammalian cells. Nat Cell Biol. 2006; 8: 416–24.

46. Steir A, Kosiyatrakul ST, Hockemeyer D, et al. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell. 2009; 138: 786–96.

47. Waga S, Stillman B. The DNA replication fork in eukaryotic cells. Annu Rev Biochem. 1998; 67: 721–51.

48. Diede SJ, Gottschling DE. Telomerase-mediated telomere addition in vivo requires DNA primase and DNA polymerases alpha and delta. Cell. 1999; 99: 723–33.

49. Adams Martin A, Dionne I, Wellinger RJ, et al. The function of DNA polymerase alpha at telomeric G tails is important for telomere homeostasis. Mol Cell Biol. 2000; 20: 786–96.

50. Dionne I, Wellinger RJ. Processing of telomeric DNA ends requires the passage of a replication fork. Nucleic Acids Res. 1998; 26: 5365–71.

51. Adams AK, Holm C. Specific DNA replication mutations affect telomere length in Saccharomyces cerevisiae. Mol Cell Biol. 1996; 16: 4614–20.

52. Qi H, Zajkhan VA. The Saccharomyces telomere-binding protein Cdc13p interacts with both the catalytic subunit of DNA polymerase alpha and the telomerase-associated est1 protein. Genes Dev. 2000; 14: 1777–88.

53. Ray S, Karamysheva Z, Wang L, et al. Interactions between telomerase and primase physically link the telomere and chromosome replication machinery. Mol Cell Biol. 2002; 22: 5859–68.

54. Dahlen M, Sunnerhagen P, Wang TS. Replication proteins influence the maintenance of telomere length and telomerase protein stability. Mol Cell Biol. 2003; 23: 3031–42.

55. Nakamura M, Nabetani A, Mizuno T, et al. Alterations of DNA and chromatin structures at telomeres and genetic instability in mouse cells defective in DNA polymerase alpha. Mol Cell Biol. 2005; 25: 11073–88.

56. Verdun RE, Karlseder J. The DNA damage machinery and homologous recombination pathway act consecutively to protect human telomeres. Cell. 2006; 127: 709–20.

57. Dai X, Huang C, Bhusari A, et al. Molecular steps of G-overhang generation at human telomeres and its function in chromosome end protection. EMBO J. 2010; 29: 2788–801.

58. Wold MS. Replication protein A: a heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. Annu Rev Biochem. 1997; 66: 61–92.

59. Zou Y, Liu Y, Wu X, et al. Functions of human replication protein A (RPA): from DNA replication to DNA damage and stress responses. J Cell Physiol. 2006; 208: 267–73.

60. Flynn RL, Zou L. Oligonucleotide/oligosaccharide-binding fold proteins: a growing family of genome guardians. Crit Rev Biochem Mol Biol. 2010; 45: 266–75.

61. Ihode C, Daniely Y, Borowiec JA. Replication protein A (RPA): the eukaryotic SSB. Crit Rev Biochem Mol Biol. 1999; 34: 141–80.

62. Wold MS, Kelly T. Purification and characterization of replication protein A, a cellular protein required for in vitro replication of simian virus 40 DNA. Proc Natl Acad Sci USA. 1988; 85: 2523–7.

63. Zou L, Elledge SJ. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science. 2003; 300: 1542–8.

64. Smith J, Zou H, Rothstein R. Characterization of genetic interactions with RFA1: the role of RPA in DNA replication and telomere maintenance. Biochimie. 2000; 82: 71–8.

65. Ono Y, Tomita K, Matsura A, et al. A novel allele of fission yeast rad11 that causes defects in DNA repair and telomere length regulation. Nucleic Acids Res. 2003; 31: 7141–9.

66. Schramke V, Luciano P, Brevet V, et al. RPA regulates telomerase action by providing Est1p access to chromosome ends. Nat Genet. 2004; 36: 46–54.

67. Rubtsova MP, Skvortsov DA, Petrusseva IO, et al. Replication protein A modulates the activity of human telomerase in vitro. Biochemistry. 2009; 74: 92–6.

68. OpreSCO PL, Otterlei M, Graakjaer J, et al. The Werner syndrome helicase and exonuclease cooperate to resolve telomeric D loops in a manner regulated by TRF1 and TRF2. Mol Cell. 2004; 14: 763–74.

69. Sowd G, Wang H, Pretto D, et al. Replication protein A stimulates the Werner syndrome protein branch migration activity. J Biol Chem. 2009; 284: 34682–91.

70. Arnoult N, Saintome C, Ourliac-Garnier I, et al. Human POT1 is required for efficient telomere C-rich strand replication in the absence of WRN. Genes Dev. 2009; 23: 2915–24.

71. Multani AS, Chang S. WRN at telomeres: implications for aging and cancer. J Cell Sci. 2007; 120: 715–21.

72. Singh DK, Ahn B, Bohr VA. Roles of RECQ helicases in recombination based DNA repair, genomic stability and aging. Biogerontology. 2009; 10: 235–52.

73. Cheok CF, Bachrati CZ, Chan KL, et al. Roles of the Bloom’s syndrome helicase in the maintenance of genome stability. Biochem Soc Trans. 2005; 33: 1456–9.

74. Sinclair DA, Mills K, Guarente L. Accelerated aging and nucleolar fragmentation in yeast sgs1 mutants. Science. 1997; 277: 1313–6.

75. Lee JY, Kozak M, Martin JD, et al. Evidence that a RecQ helicase slows senescence by resolving recombining telomeres. PLoS Biol. 2007; 5: 1334–44.

76. Lu CY, Tsai CH, Brill SJ, et al. Sumoylation of the BLM ortholog, Sgs1, promotes telomere-telomere recombination in budding yeast. Nucleic Acids Res. 2010; 38: 488–98.

77. Bai Y, Murnane JP. Telomere instability in a human tumor cell line expressing a dominant-negative WRN protein. Hum Genet. 2003; 113: 337–47.

78. Crabbe L, Verduin RE, Haggblom CI, et al. Defective telomere lagging strand
synthesis in cells lacking WRN helicase activity. Science. 2004; 306: 1951–3.
79. Chang S, Multani AS, Cabrera NG, et al. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nat Genet. 2004; 36: 877–82.
80. Du X, Shen J, Kogan N, et al. Telomere shortening exposes functions for the mouse Werner and Bloom syndrome genes. Mol Cell Biol. 2004; 24: 8437–46.
81. Opresko PL, Mason PA, Podell ER, et al. POT1 stimulates RecQ helicases WRN and BLM to unwind telomeric DNA substrates. J Biol Chem. 2005; 280: 32069–80.
82. Li JI, Harrison RJ, Reszka AP, et al. Inhibition of the Bloom’s and Werner’s syndrome helicases by G-quadruplex interacting ligands. Biochemistry. 2001; 40: 15194–202.
83. Opresko PL, von Kobbe C, Laine JP, et al. Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases. J Biol Chem. 2002; 277: 41110–9.
84. Machwe A, Xiao L, Orren DK. TRF2 recruits the Werner syndrome (WRN) exonuclease for processing of telomeric DNA. Oncogene. 2004; 23: 149–56.
85. Schroeder TM, German J. Bloom’s syndrome and Fanconi anemia: demonstration of two distinctive patterns of chromosome disruption and rearrangement. Humangenetik. 1974; 25: 299–306.
86. German J, Bloom D, Passarge E, et al. Bloom's syndrome. VI. The disorder in Israel and an estimation of the gene frequency in the Ashkenazim. Am J Hum Genet. 1977; 29: 553–62.
87. German J, Bloom D, Passarge E. Bloom’s syndrome. V. Surveillance for cancer in affected families. Clin Genet. 1977; 12: 162–8.
88. Brosh RM Jr, Majumdar A, Desai S, et al. Unwinding of a DNA triple helix by the Werner and Bloom syndrome helicases. J Biol Chem. 2001; 276: 3024–30.
89. Mohaghegh P, Karow JK, Brosh RM Jr, et al. The Bloom’s and Werner’s syndrome proteins are DNA structure-specific helicases. Nucleic Acids Res. 2001; 29: 2843–9.
90. Lillard-W etherell K, Machwe A, Langland GT, et al. Association and regulation of the BLM helicase by the telomere proteins TRF1 and TRF2. Hum Mol Genet. 2004; 13: 1919–32.
91. Harrington JJ, Lieber MR. The characterization of a mammalian DNA structure-specific endonuclease. EMBO J. 1994; 13: 1235–46.
92. Liu Y, Kao HI, Bambara RA. Flap endonuclease 1: a central component of DNA metabolism. Annu Rev Biochem. 2004; 73: 589–615.
93. Shen B, Singh P, Liu R, et al. Multiple but dissectionable functions of FEN-1 nuclease in nucleic acid processing, genome stability and diseases. Bioessays. 2005; 27: 717–29.
94. Murante RS, Rust L, Bambara RA. Calf 5’ to 3’ exo/endonuclease must slide from a 5’ end of the substrate to perform structure-specific cleavage. J Biol Chem. 1995; 270: 30377–83.
95. Lyamichev V, Brow MA, Dahlberg JE. Structure-specific endonucleolytic cleavage of nucleic acids by eubacterial DNA polymerases. Science. 1993; 260: 778–83.
96. Kao HI, Campbell JL, Bambara RA. Dna2p helicase/nuclease is a tracking protein, like FEN1, for flap cleavage during Okazaki fragment maturation. J Biol Chem. 2004; 279: 50840–9.
97. Parenteau J, Wellinger RJ. Accumulation of single-stranded DNA and destabilization of telomeric repeats in yeast mutant strains carrying a deletion of RAD27. Mol Cell Biol. 1999; 19: 4143–52.
98. Parenteau J, Wellinger RJ. Differential processing of leading- and lagging-strand ends at Saccharomyces cerevisiae telomeres revealed by the absence of Rad27p nuclease. Genetics. 2002; 162: 1583–94.
99. Muthuoglu M, Wong HK, Imam SZ, et al. Telomere repeat binding factor 2 interacts with base excision repair proteins and stimulates DNA synthesis by DNA polymerase beta. Cancer Res. 2006; 66: 113–24.
100. Sampathi S, Bhusari A, Shen B, et al. Human flap endonuclease I is in complex with telomerase and is required for telomerase-mediated telomere maintenance. J Biol Chem. 2009; 284: 3862–90.
101. Saharia A, Guittat L, Crocker S, et al. Flap endonuclease 1 contributes to telomere stability. Curr Biol. 2008; 18: 496–500.
102. Zheng L, Zhou M, Chai Q, et al. Novel function of the flap endonuclease 1 complex in processing stalled DNA replication forks. EMBO Rep. 2005; 6: 83–9.
103. Saharia A, Teasley DC, Duxin JP, et al. FEN1 ensures telomere stability by facilitating replication fork re-initiation. J Biol Chem. 2010; 285: 27057–66.
104. Sharma S, Sommers JA, Gary RK, et al. The interaction site of Flap Endonuclease-1 with WRN helicase suggests a coordination of WRN and PCNA. Nucleic Acids Res. 2005; 33: 6679–81.
105. Vallur AC, Maizels N. Distinct activities of exonuclease 1 and flap endonuclease 1 at telomeric g4 DNA. PLoS ONE. 2010; 5: 1–9.
106. Choe W, Budd M, Imamura O, et al. Dynamic localization of an Okazaki fragment processing protein suggests a novel role in telomere replication. Mol Cell Biol. 2002; 22: 4202–17.
107. Tomita K, Kibe T, Kang HY, et al. Fission yeast DNA2 is required for generation of the telomeric single-strand overhang. Mol Cell Biol. 2004; 24: 9557–67.
108. Miller KM, Rog O, Cooper JP. Semi-conservative DNA replication through telomeres requires Taz1. Nature. 2008; 440: 824–8.
109. Ye J, Lenain C, Bauwens S, et al. TRF2 and Apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell. 2010; 142: 230–42.
110. Amiard S, Dousseau M, Pinte S, et al. A topological mechanism for TRF2-enhanced strand invasion. Nat Struct Mol Biol. 2007; 14: 147–54.
111. Tatsumi Y, Ezura K, Yoshida K, et al. Involvement of human ORC and TRF2 in pre-replication complex assembly at telomeres. Genes Cells. 2008; 13: 1045–59.
112. Deng Z, Dheekollu J, Broccoli D, et al. The origin recognition complex localizes to telomere repeats and prevents telomere-circle formation. Curr Biol. 2007; 17: 1989–95.
113. Kirth I, Gautier J. Origin-dependent initiation of DNA replication within telomeric sequences. Nucleic Acids Res. 2010; 38: 467–76.
114. Giannone RJ, McDonald HW, Hurst GB, et al. The Protein Network Surrounding the Human Telomere Repeat Binding Factors TRF1, TRF2, and POT1. PLoS ONE. 2010; 5: 1–10.
115. Kim H, Lee OH, Xin H, et al. TRF2 functions as a protein hub and regulates telomere maintenance by recognizing specific peptide motifs. Nat Struct Mol Biol. 2009; 16: 372–9.
116. Lennon G, Bauwens S, Amiard S, et al. The Apollo 5’ exonuclease functions together with TRF2 to protect telomeres from DNA repair. Curr Biol. 2006; 16: 1303–10.
117. van Overbeek M, de Lange T. Apollo, an Artemis-related nuclease, interacts with TRF2 and protects human telomeres in S phase. Curr Biol. 2006; 16: 1295–302.
118. Yang Q, Zheng YL, Harris CC. POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol. 2005; 25: 1070–80.
119. Hockemeyer D, Daniels JP, Takai H, et al. Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres. *Cell*. 2006; 126: 63–77.

120. Hockemeyer D, Palm W, Else T, et al. Telomere protection by mammalian Pot1 requires interaction with Tpp1. *Nat Struct Mol Biol*. 2007; 14: 754–61.

121. Hockemeyer D, Steir AJ, Shay JW, et al. POT1 protects telomeres from a transient DNA damage response and determines how human chromosomes end. *EMBO J*. 2005; 24: 2667–76.

122. Ye JZ, Hockemeyer D, Krutchinsky AN, et al. POT1-interacting protein PIP1: a telomere length regulator that recruits POT1 to the TIN2/TRF1 complex. *Genes Dev*. 2004; 18: 1649–54.

123. Denchi EL, de Lange T. Protection of telomeres through independent control of ATM and ATR by TRF2 and POT1. *Nature*. 2007; 448: 1068–71.

124. Wu L, Multani AS, He H, et al. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. *Cell*. 2006; 126: 49–62.

125. Wellinger RJ, Wolf AJ, Zakian VA. Saccharomyces telomeres acquire single-strand TG1–3 tails late in S phase. *Cell*. 1993; 72: 51–60.

126. Nugent CI, Hughes TR, Lue NF, et al. Cdc13p: a single-strand telomeric DNA-binding protein with a dual role in yeast telomere maintenance. *Science*. 1996; 274: 249–52.

127. Zhao Y, Steir AJ, Zou Y, et al. Telomere extension occurs at most chromosome ends and is uncoupled from fill-in in human cancer cells. *Cell*. 2009; 138: 463–75.

128. Surovtseva YV, Churikov D, Boltz KA, et al. Conserved Telomere Maintenance Component 1 Interacts with STN1 and Maintains Chromosome Ends in Higher Eukaryotes. *Mol Cell*. 2009; 36: 207–18.

129. Miyake Y, Nakamura M, Nabetani A, et al. RPA-like mammalian Ctc1-Stn1-Ten1 complex binds to single-stranded DNA and protects telomeres independently of the Pot1 pathway. *Mol Cell*. 2009; 36: 193–206.

130. Chandra A, Hughes TR, Nugent CI, et al. Cdc13 cooperates with yeast Ku proteins and Sfn1 to regulate telomerase recruitment. *EMBO J*. 2001; 20: 404–14.

131. Grandin N, Damon C, Charbonneau M. Cdc13 cooperates with the yeast Ku proteins and Sfn1 to regulate telomerase recruitment. *Mol Cell Biol*. 2000; 20: 8397–408.

132. Grandin N, Damon C, Charbonneau M. Ten1 functions in telomere end protection and length regulation in association with Sfn1 and Cdc13. *EMBO J*. 2001; 20: 1173–83.

133. Grandin N, Reed SI, Charbonneau M. Stn1, a new Saccharomyces cerevisiae protein, is implicated in telomere size regulation in association with Cdc13. *Genes Dev*. 1997; 11: 512–27.

134. Casteel DE, Zhuang S, Zeng Y, et al. A DNA polymerase-α/primase cofactor with homology to replication protein A-32 regulates DNA replication in mammalian cells. *J Biol Chem*. 2009; 284: 5807–18.

135. Wan M, Qin J, Songyang Z, et al. OB-fold containing protein 1 (OBFC1), a human homologue of yeast Stn1, associates with TPP1 and is implicated in telomere length regulation. *J Biol Chem*. 2009; 284: 26725–31.

136. Levy D, Neuhausen SL, Hunt SC, et al. Genome-wide association identifies OBFC1 as a locus involved in human leukocyte telomere biology. *Proc Natl Acad Sci USA*. 2010; 107: 9293–8.

© 2011 The Author
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd